AHA ASA acute stroke alteplase rTPA update 2016 khotailieu y hoc
➤ Gửi thông báo lỗi ⚠️ Báo cáo tài liệu vi phạmNội dung chi tiết: AHA ASA acute stroke alteplase rTPA update 2016 khotailieu y hoc
AHA ASA acute stroke alteplase rTPA update 2016 khotailieu y hoc
AHA/ASA Scientific StatementScientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke A Stateme AHA ASA acute stroke alteplase rTPA update 2016 khotailieu y hocent for Healthcare Professionals From the American Heart Association/American Stroke Associationfrom hBp://sỉroke.ahjyoun»13.ocg’’ bỉ' guest on January 11,2017The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists.Endorsed by the American Associ AHA ASA acute stroke alteplase rTPA update 2016 khotailieu y hocation of Neurological Surgeons and Congress of Neurological SurgeonsBart M. Demaerschalk. MD. MSc. FRCPC. FAHA. Chair:Dawn o. Kleindorfer. MD. FAHA. VAHA ASA acute stroke alteplase rTPA update 2016 khotailieu y hoc
ice-Chair: Opeolu M. Adeoye. MD. MS. FAHA: Andrew M. Demchuk. MD: Jennifer E. Fugate. DO; James c. Grotta. MD; Alexander A. Khalessi. MD. MS. FAHA: ElAHA/ASA Scientific StatementScientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke A Stateme AHA ASA acute stroke alteplase rTPA update 2016 khotailieu y hocith. MD. MPH. FAHA: on behalf of the American Heart Association Stroke Council and Council on Epidemiology and PreventionPurpose—To critically review and evaluate the science behind individual eligibility criteria (indication/inelusion and contraindications/exclusion criteria) for intravenous recomb AHA ASA acute stroke alteplase rTPA update 2016 khotailieu y hocinant tissue-type plasminogen activator (alteplase) treatment in acute ischemic stroke. This will allow US to better inform stroke providers of quantiAHA ASA acute stroke alteplase rTPA update 2016 khotailieu y hoc
tative and qualitative risks associated with altcplasc administration under selected commonly and uncommonly encountered clinical circumstances and toAHA/ASA Scientific StatementScientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke A Stateme AHA ASA acute stroke alteplase rTPA update 2016 khotailieu y hoc improve outcomes after stroke.Methods—Writing group members were nominated by the committee chair on the basis of their previous work in relevant topic areas and were approved by the American Heart Association StrokeijCouneirs Scientific Statement Oversight Committee and the American Henn Associati AHA ASA acute stroke alteplase rTPA update 2016 khotailieu y hocon's Manuscript Oversight Committee. The writers used systematic literature reviews, references to published clinical and epidemiology studies, mvibidAHA ASA acute stroke alteplase rTPA update 2016 khotailieu y hoc
ity and mortality reports, clinical and public health guidelines, authoritative statements, personal files, and expert opinion to summarize existing eAHA/ASA Scientific StatementScientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke A Stateme AHA ASA acute stroke alteplase rTPA update 2016 khotailieu y hoc. All members of the writing group had the opportunity to comment on and approved the final version of this document. The document underwent extensive American Heart Association internal peer review. StrokeThe American Heart Association makes every effort to avoid any actual or potential conflicts o AHA ASA acute stroke alteplase rTPA update 2016 khotailieu y hocf interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. SAHA ASA acute stroke alteplase rTPA update 2016 khotailieu y hoc
pecifically, all members of the w riling group arc required to complete 31X1 submit a Disclosure Questionnaire showing all such relationships that migAHA/ASA Scientific StatementScientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke A Stateme AHA ASA acute stroke alteplase rTPA update 2016 khotailieu y hocting Committee on September 24. 2015. and the American Heart Association Executive Committee on October 5. 2015. A copy of the document IS available al http://my.amencanheart.org/statements by selecting either the "By Topic" link or the "By Publication Dale- link. To purchase additional reprints, ca AHA ASA acute stroke alteplase rTPA update 2016 khotailieu y hocll 843-216-2533 or e-mail kelle nimsay^ wolterskluwer.com.The online-only Data Supplement, which contains literature search strategies and Figures A.AHA ASA acute stroke alteplase rTPA update 2016 khotailieu y hoc
B. and c. Is available with this article al http://cire. uhajoumats.or&'lookup'suppi/diH: in. I Ifcl/M R.mMXMXNXXXMMXMNr^lM'l.The American Heart AssocAHA/ASA Scientific StatementScientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke A Stateme AHA ASA acute stroke alteplase rTPA update 2016 khotailieu y hocy El. Palesch YY. Pnibhakaran s. Saposnik G. Saver JL. Smith EE; on behalf of the American Heart Association Stroke Council and Council on Epidemiology and Prevention. Scientific rationale for the inclusion and exclusion criteria for intravenous altepla.se in acute ischemic stroke: a statement for h AHA ASA acute stroke alteplase rTPA update 2016 khotailieu y hocealthcare professionals from the American Heart Associafion/American Stroke Association Stroke 2OI6;47:XXX-XXX.Expert peer review of AHA Scientific StAHA ASA acute stroke alteplase rTPA update 2016 khotailieu y hoc
atements is conducted by the AHA Office of Science Operations. For more on AHA statements and guidelines development, visit http://my.americanheart.o<AHA/ASA Scientific StatementScientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke A Stateme AHA ASA acute stroke alteplase rTPA update 2016 khotailieu y hocof this document are not permitted without the express permission of live American Heart Association. Instructions for obtaining permission are located at hllpy/ww w.lveart.org/HEARTORG/GeneraliCopyright-Pcrmission-Guidelincs_UCM_30(>404_Arliclc.j.5p. A link to the "Copyright Permissions Request For AHA ASA acute stroke alteplase rTPA update 2016 khotailieu y hocm" appears on the right side of the page.Ô 2015 American Heart Association, Inc.Stroke Is available at hltp://slroke.ahaj<>unuils.<>qcDOI: 10.1 l61>'SAHA ASA acute stroke alteplase rTPA update 2016 khotailieu y hoc
TR.lMKHMHHMI0tKHMHJ86/2 Stroke February 2016Council Leadership review, and Scientific Statements Oversight Committee review before consideration and aAHA/ASA Scientific StatementScientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke A Stateme AHA ASA acute stroke alteplase rTPA update 2016 khotailieu y hocevident that the levels of evidence supporting individual exclusion criteria for intravenous alteplase vary widely. Several exclusionary criteria have already undergone extensive scientific study such as the deal- benefit of aheplase treatment in elderly stroke patients, those with severe stroke, th AHA ASA acute stroke alteplase rTPA update 2016 khotailieu y hocose with diabetes mellitus and hyperglycemia, and those with minor early ischemic changes evident on computed tomography. Some exclusions such as receAHA ASA acute stroke alteplase rTPA update 2016 khotailieu y hoc
nt intracranial surgery are likely based on common sense and sound judgment and arc unlikely to ever be subjected to a randomized, clinical trial to eAHA/ASA Scientific StatementScientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke A Stateme AHA ASA acute stroke alteplase rTPA update 2016 khotailieu y hoces not only with the evidence base behind it but also with the frequency of the exclusion within the stroke population, the probability of coexistence of multiple exclusion factors in a single patient, and the variation in practice among treating clinicians. [Stroke. 2016:47:00-00. DOI: 10.1161/STR. AHA ASA acute stroke alteplase rTPA update 2016 khotailieu y hoc0000000000000086.1Key Words: AHA Scientific Statements ■ brain ischemia ■ cerebral infarction ■ fibrinolytic agents ■ stroke■ thrombolytic therapy ■ (AHA ASA acute stroke alteplase rTPA update 2016 khotailieu y hoc
issue plasminogen activatorDownloaded fiom http: suoke.ahajMiinals.oig by guest OU JaiUkvy 11. 2017For our exclusion criteria, we elected to focus onlAHA/ASA Scientific StatementScientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke A Stateme AHA ASA acute stroke alteplase rTPA update 2016 khotailieu y hocUS Food and Drug Administration (FDA) package insert, specifically for the only tissue-type plasminogen activator licensed for use in acuteischemic stroke, alteplase. We did not include international guidelines or other international governmental restrictions on the use of alteplase because it was b AHA ASA acute stroke alteplase rTPA update 2016 khotailieu y hoceyond the scope of this document. However, we included data from international studies in our review of the literature for each exclusion. LiteratureAHA ASA acute stroke alteplase rTPA update 2016 khotailieu y hoc
search Strategies are publis s,an online-only Data Supplement.We have also intentionally focusc on any or all types of thrombolytic agent?, trated on AHA/ASA Scientific StatementScientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke A Stateme AHA ASA acute stroke alteplase rTPA update 2016 khotailieu y hocates. Although some hospital and quality registry estimates of altcplase treatment rates can range as high as 20% to 30%,'M national estimates of use have ranged only from 3% to 5% since 2004.910 Although these rates of treatment are quite low. they are improving slowly over time. This low use IS li AHA ASA acute stroke alteplase rTPA update 2016 khotailieu y hockelyattributable to a number of reasons, including the paucity of community public education abiMU recognition and response to acute stroke symptoms aAHA ASA acute stroke alteplase rTPA update 2016 khotailieu y hoc
nd signs, the slow adoption of the medication in the medical community, and the complexity of huge system changes at tile hospital level iChat are necAHA/ASA Scientific StatementScientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke A Stateme AHA ASA acute stroke alteplase rTPA update 2016 khotailieu y hoc for low treatment is the low eligibility rate for thisncr.controversies and approvals for these different approaches arc many and currently arc not as generalizable as the FDA-approved intravenous administration of alteplase.Recommendations were formulated with the use of standard AHA criteria (Tab AHA ASA acute stroke alteplase rTPA update 2016 khotailieu y hocles 1 and 2). All members of the writing group had the opportunity to comment on the recommendations and approved the final version of this document.AHA ASA acute stroke alteplase rTPA update 2016 khotailieu y hoc
The document underwent extensive AHA internal peer review. Stroke Council Leadership review, and Scientific Statements Oversight Committee review befoGọi ngay
Chat zalo
Facebook